Marketdash
Back to News

Five Wall Street Upgrades: Eaton Gets Bullish Call, Lyell Immunopharma Price Target Doubles

MarketDash Editorial Team
16 hours ago
Wall Street analysts upgraded five stocks on Tuesday, with Eaton Corporation, Colgate-Palmolive, and Lyell Immunopharma among those getting bullish calls. Here's what changed and where analysts see these stocks heading.

A handful of Wall Street analysts decided Tuesday was a good day to get more bullish, issuing upgrades across industrial, consumer, biotech, and semiconductor names. The moves ranged from modest rating bumps to dramatic price target increases that suggest some analysts think they've been missing something.

Here's what changed and where these stocks stood after the calls.

Eaton Gets Industrial Strength Upgrade

Wolfe Research analyst Nigel Coe upgraded Eaton Corporation plc (ETN) from Peer Perform to Outperform and set a $413 price target. That represents about 20% upside from Monday's closing price of $343.39. The industrial power management company has been riding momentum in data center infrastructure and electrical equipment demand, and it looks like Coe thinks there's more room to run.

Consumer Staples Get Fresh Look

RBC Capital analyst Nik Modi upgraded Colgate-Palmolive Company (CL) from Sector Perform to Outperform with an $88 price target. The stock closed at $76.11 on Monday, so Modi is betting on about 16% upside for the toothpaste and personal care giant. It's the kind of upgrade that suggests the consumer staples sector might be looking more interesting after a period of being overlooked.

Over at RPM International Inc. (RPM), RBC Capital analyst Arun Viswanathan also turned more optimistic, upgrading the specialty chemicals and coatings company from Sector Perform to Outperform. He boosted his price target from $121 to $132, well above Monday's close of $102.63. That's nearly 29% upside if Viswanathan's thesis plays out.

Biotech Gets Dramatic Vote of Confidence

The most eye-catching move came from HC Wainwright analyst Mitchell S. Kapoor, who upgraded Lyell Immunopharma, Inc. (LYEL) from Neutral to Buy and more than doubled his price target from $20 to $45. The stock closed Monday at $28.36, so Kapoor is calling for nearly 59% upside. That's not a subtle call—it's the kind of upgrade that signals a meaningful change in how an analyst views a company's prospects.

Chip Design Software Gets Measured Optimism

Rosenblatt analyst Blair Abernethy upgraded Synopsys, Inc. (SNPS) from Neutral to Buy, though he actually lowered his price target from $605 to $560. The electronic design automation company closed Friday at $465.75, so even with the reduced target, Abernethy sees about 20% upside. The upgrade with a lower price target is an interesting combo—it suggests the analyst is more confident in the story even as near-term expectations moderate.

These upgrades come at a time when investors are hunting for opportunities across sectors, from defensive consumer names to high-growth biotech to industrial powerhouses benefiting from infrastructure spending. Whether these analysts are early to a trend or catching the tail end of momentum will become clearer in the coming months.

Back to News

Five Wall Street Upgrades: Eaton Gets Bullish Call, Lyell Immunopharma Price Target Doubles

MarketDash Editorial Team
16 hours ago
Wall Street analysts upgraded five stocks on Tuesday, with Eaton Corporation, Colgate-Palmolive, and Lyell Immunopharma among those getting bullish calls. Here's what changed and where analysts see these stocks heading.

A handful of Wall Street analysts decided Tuesday was a good day to get more bullish, issuing upgrades across industrial, consumer, biotech, and semiconductor names. The moves ranged from modest rating bumps to dramatic price target increases that suggest some analysts think they've been missing something.

Here's what changed and where these stocks stood after the calls.

Eaton Gets Industrial Strength Upgrade

Wolfe Research analyst Nigel Coe upgraded Eaton Corporation plc (ETN) from Peer Perform to Outperform and set a $413 price target. That represents about 20% upside from Monday's closing price of $343.39. The industrial power management company has been riding momentum in data center infrastructure and electrical equipment demand, and it looks like Coe thinks there's more room to run.

Consumer Staples Get Fresh Look

RBC Capital analyst Nik Modi upgraded Colgate-Palmolive Company (CL) from Sector Perform to Outperform with an $88 price target. The stock closed at $76.11 on Monday, so Modi is betting on about 16% upside for the toothpaste and personal care giant. It's the kind of upgrade that suggests the consumer staples sector might be looking more interesting after a period of being overlooked.

Over at RPM International Inc. (RPM), RBC Capital analyst Arun Viswanathan also turned more optimistic, upgrading the specialty chemicals and coatings company from Sector Perform to Outperform. He boosted his price target from $121 to $132, well above Monday's close of $102.63. That's nearly 29% upside if Viswanathan's thesis plays out.

Biotech Gets Dramatic Vote of Confidence

The most eye-catching move came from HC Wainwright analyst Mitchell S. Kapoor, who upgraded Lyell Immunopharma, Inc. (LYEL) from Neutral to Buy and more than doubled his price target from $20 to $45. The stock closed Monday at $28.36, so Kapoor is calling for nearly 59% upside. That's not a subtle call—it's the kind of upgrade that signals a meaningful change in how an analyst views a company's prospects.

Chip Design Software Gets Measured Optimism

Rosenblatt analyst Blair Abernethy upgraded Synopsys, Inc. (SNPS) from Neutral to Buy, though he actually lowered his price target from $605 to $560. The electronic design automation company closed Friday at $465.75, so even with the reduced target, Abernethy sees about 20% upside. The upgrade with a lower price target is an interesting combo—it suggests the analyst is more confident in the story even as near-term expectations moderate.

These upgrades come at a time when investors are hunting for opportunities across sectors, from defensive consumer names to high-growth biotech to industrial powerhouses benefiting from infrastructure spending. Whether these analysts are early to a trend or catching the tail end of momentum will become clearer in the coming months.